Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)

Amgen

Amgen clinical programs — 51 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
One Amgen Center Drive, Thousand Oaks, CA 91320, US
Founded
1980
Employees
40,212
Programs
96
Drugs
124
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Amgen projects

51 ClinicalTrials.gov programs sponsored by Amgen.

Amgen has 51 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

51 programs

Clinical programs

Page 1 of 2

  1. 20170724

    Amgen

    Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis

    phase 3 small molecule active

    1 trial

  2. 20170770

    Amgen

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  3. 20190009

    Amgen

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  4. 20190172

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  5. 20190360

    Amgen

    Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults

    phase 3 small molecule active

    1 trial

  6. 20190529

    Amgen

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  7. 20190531

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  8. 20200041

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  9. 20210081

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  10. 20210096

    Amgen

    Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression

    phase 3 small molecule active

    1 trial

  11. 20210098

    Amgen

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  12. 20210184

    Amgen

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  13. 20220043

    Amgen

    Osteogenesis Imperfecta

    phase 3 small molecule active

    1 trial

  14. 20220196

    Amgen

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  15. 20230005

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  16. 20230016

    Amgen

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  17. 20230127

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  18. 20230225

    Amgen

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  19. 20230227

    Amgen

    Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    phase 3 small molecule active

    1 trial

  20. 20230239

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  21. 20230309

    Amgen

    Relapsing-remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  22. 20240178

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  23. ABP 206

    Amgen

    Melanoma

    phase 3 small molecule active

    2 trials

  24. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  25. AMG386 plus PLD

    Amgen

    Fallopian Tube Cancer

    phase 3 small molecule terminated

    1 trial

  26. Apremilast 20mg

    Amgen

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  27. Atorvastatin

    Amgen

    Hyperlipidemia

    phase 3 small molecule completed

    1 trial

  28. Carfilzomib

    Amgen

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials

  29. Cetuximab

    Amgen

    Metastatic Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  30. Darbepoetin alfa

    Amgen

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  31. Dazodalibep

    Amgen

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  32. Denosumab

    Amgen

    Cancer

    phase 3 small molecule completed

    1 trial

  33. Dexamethasone

    Amgen

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  34. Erenumab, Placebo for AMG 334

    Amgen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  35. Etelcalcetide

    Amgen

    Hyperparathyroidism, Secondary

    phase 3 small molecule completed

    1 trial

  36. Etelcalcetide

    Amgen

    Secondary Hyperparathyroidism

    phase 3 small molecule completed

    1 trial

  37. Evolocumab

    Amgen

    Hyperlipidemia

    phase 3 mab completed

    2 trials

  38. Evolocumab

    Amgen

    Severe Familial Hypercholesterolemia

    phase 3 mab completed

    1 trial

  39. Evolocumab

    Amgen

    Coronary Heart Disease (CHD)

    phase 3 small molecule completed

    1 trial

  40. Evolocumab

    Amgen

    Dyslipidemia

    phase 3 mab completed

    1 trial

  41. Maridebart cafraglutide

    Amgen

    Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

    phase 3 small molecule active

    1 trial

  42. Olpasiran, Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  43. Panitumumab

    Amgen

    Metastatic Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  44. Placebo

    Amgen

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  45. Placebo for AMG 145, EVOLOCUMAB

    Amgen

    Adults at high risk of cardiovascular events without prior MI or stroke.

    phase 3 small molecule active

    1 trial

  46. Placebo for AMG 334, Erenumab

    Amgen

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  47. Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  48. Rilotumumab

    Amgen

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Amgen have?

51 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.